C
Christin Tse
Researcher at Abbott Laboratories
Publications - 12
Citations - 2832
Christin Tse is an academic researcher from Abbott Laboratories. The author has contributed to research in topics: Cancer & Mantle cell lymphoma. The author has an hindex of 9, co-authored 12 publications receiving 2591 citations.
Papers
More filters
Journal ArticleDOI
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse,Alexander R. Shoemaker,Jessica Adickes,Mark G. Anderson,Jun Chen,Sha Jin,Eric F. Johnson,Kennan C. Marsh,Michael J. Mitten,Paul Nimmer,Lisa R. Roberts,Stephen K. Tahir,Yu Xiao,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +17 more
TL;DR: The biological properties and rationale for clinical trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies are provided and the oral efficacy should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens are reported.
Journal ArticleDOI
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Cheol-Min Park,Milan Bruncko,Jessica Adickes,Joy Bauch,Hong Ding,Kunzer Aaron R,Kennan C. Marsh,Paul Nimmer,Alexander R. Shoemaker,Xiaohong Song,Stephen K. Tahir,Christin Tse,Wang Xilu,Michael D. Wendt,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +18 more
TL;DR: Targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC 50).
Journal ArticleDOI
Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
Stephen K. Tahir,Xiufen Yang,Mark G. Anderson,Susan Morgan-Lappe,Aparna Sarthy,Jun Chen,Robert B. Warner,Shi-Chung Ng,Stephen W. Fesik,Steve W. Elmore,Saul H. Rosenberg,Christin Tse +11 more
TL;DR: Observations provide further insight as to the mechanistic bases for ABT-737 efficacy in SCLC and will be helpful for profiling patients and aiding in the rational design of combination therapies.
Journal ArticleDOI
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Alex R. Shoemaker,Michael J. Mitten,Jessica Adickes,Scott L. Ackler,Marion Refici,Debra Ferguson,Anatol Oleksijew,Jacqueline M. O'Connor,Baole Wang,David Frost,Joy Bauch,Kennan C. Marsh,Steven K. Tahir,Xiufen Yang,Christin Tse,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +17 more
TL;DR: The efficacy data reported here suggest that SCLC is a promising area of clinical investigation with this agent, and ABT-263 is a potent, orally bioavailable inhibitor of Bcl-2 family proteins that has recently entered clinical trials.
Journal ArticleDOI
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
Scott L. Ackler,Michael J. Mitten,Kelly Foster,Anatol Oleksijew,Marion Refici,Stephen K. Tahir,Yu Xiao,Christin Tse,David Frost,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore,Alexander R. Shoemaker +12 more
TL;DR: Inhibition of the Bcl-2 family of proteins by ABT-263 enhances the cytotoxicity of multiple chemotherapeutic agents and regimens in hematologic tumors and represents a promising addition to the therapeutic arsenal for treatment of these diseases.